Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis

Autoimmunity Reviews

Volumn 9, Issue 3, 2010, Pages 140-143

  Szodoray, Péter ^a   Szabó, Zoltán ^b   Kapitány, Anikó ^b   Gyetvai, Ágnes ^b   Lakos, Gabriella ^b   Szántó, Sándor ^b   Szücs, Gabriella ^b   Szekanecz, Zoltán ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

ACPA; Anti CCP; Autoimmunity; Genetics; HLA DR; Rheumatoid arthritis; Shared epitope

Indexed keywords

ARGININE; AUTOANTIBODY; C REACTIVE PROTEIN; CAFFEINE; CD16 ANTIGEN; CITRULLINATED PROTEIN/PEPTIDE AUTOANTIBODY; CITRULLINE; FC GAMMA RECEPTOR IIIA; FIBRIN; FILAGGRIN; ORAL CONTRACEPTIVE AGENT; RHEUMATOID FACTOR; STROMELYSIN; UNCLASSIFIED DRUG; VIMENTIN;

ALLELE; APOPTOSIS; AUTOIMMUNITY; DISEASE ASSOCIATION; DISEASE COURSE; ENVIRONMENTAL FACTOR; ERYTHROCYTE SEDIMENTATION RATE; GENOTYPE; HEREDITY; HUMAN; JOINT DESTRUCTION; KERATINIZATION; LIFESTYLE; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; PROTEIN MODIFICATION; PSORIATIC ARTHRITIS; RADIOGRAPHY; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SYNOVIUM;

ANIMALS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CITRULLINE; GENETIC TESTING; HUMANS; PEPTIDES; PROGNOSIS;

EID: 72149113840     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.04.006     Document Type: Review

References (40)

1. Alamanos Y., and Drosos A.A. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 4 3 (2005) 130-136
2. van der Helm-van Mil A.H., Wesoly J.Z., and Huizinga T.W. Understanding the genetic contribution to rheumatoid arthritis. Curr Opin Rheumatol 17 3 (2005) 299-304
3. Raza K., Buckley C.E., Salmon M., and Buckley C.D. Treating very early rheumatoid arthritis. Best Pract Res Clin Rheumatol 20 5 (2006) 849-863
4. Klareskog L., Widhe M., Hermansson M., and Ronnelid J. Antibodies to citrullinated proteins in arthritis: pathology and promise. Curr Opin Rheumatol 20 3 (2008) 300-305
5. Suzuki A., Yamada R., and Yamamoto K. Citrullination by peptidylarginine deiminase in rheumatoid arthritis. Ann N Y Acad Sci 1108 (2007) 323-339
6. Vossenaar E.R., Radstake T.R., van der Heijden A., van Mansum M.A., Dieteren C., de Rooij D.J., et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 63 4 (2004) 373-381
7. Sebbag M., Chapuy-Regaud S., Auger I., Petit-Texeira E., Clavel C., Nogueira L., et al. Clinical and pathophysiological significance of the autoimmune response to citrullinated proteins in rheumatoid arthritis. Joint Bone Spine 71 6 (2004) 493-502
8. Szekanecz Z., Soos L., Szabo Z., Fekete A., Kapitany A., Vegvari A., et al. Anti-citrullinated protein antibodies in rheumatoid arthritis: as good as it gets?. Clin Rev Allergy Immunol 34 1 (2008) 26-31
9. Simon M., Girbal E., Sebbag M., Gomes-Daudrix V., Vincent C., Salama G., et al. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis. J Clin Invest 92 3 (1993) 1387-1393
10. Soos L., Szekanecz Z., Szabo Z., Fekete A., Zeher M., Horvath I.F., et al. Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. J Rheumatol 34 8 (2007) 1658-1663
11. Snir O., Widhe M., von Spee C., Lindberg J., Padyukov L., Lundberg K., et al. Multiple antibody reactivities to citrullinated antigens in sera from patients with rheumatoid arthritis: association with HLA-DRB1 alleles. Ann Rheum Dis 68 5 (2009) 736-743
12. Takizawa Y., Suzuki A., Sawada T., Ohsaka M., Inoue T., Yamada R., et al. Citrullinated fibrinogen detected as a soluble citrullinated autoantigen in rheumatoid arthritis synovial fluids. Ann Rheum Dis 65 8 (2006) 1013-1020
13. Vossenaar E.R., Despres N., Lapointe E., van der Heijden A., Lora M., Senshu T., et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 6 2 (2004) R142-R150
14. Schellekens G.A., Visser H., de Jong B.A., van den Hoogen F.H., Hazes J.M., Breedveld F.C., et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 43 1 (2000) 155-163
15. Sebbag M., Moinard N., Auger I., Clavel C., Arnaud J., Nogueira L., et al. Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. Eur J Immunol 36 8 (2006) 2250-2263
16. Vossenaar E.R., Smeets T.J., Kraan M.C., Raats J.M., van Venrooij W.J., and Tak P.P. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 50 11 (2004) 3485-3494
17. Alenius G.M., Berglin E., and Rantapaa Dahlqvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint inflammation. Ann Rheum Dis 65 3 (2006) 398-400
18. Nell V.P., Machold K.P., Stamm T.A., Eberl G., Heinzl H., Uffmann M., et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 64 12 (2005) 1731-1736
19. van Venrooij W.J., van Beers J.J., and Pruijn G.J. Anti-CCP antibody, a marker for the early detection of rheumatoid arthritis. Ann N Y Acad Sci 1143 (2008) 268-285
20. Skogh T. Does a positive anti-CCP test identify a distinct arthritis entity?. Arthritis Res Ther 7 6 (2005) 230-232
21. van Jaarsveld C.H., ter Borg E.J., Jacobs J.W., Schellekens G.A., Gmelig-Meyling F.H., van Booma-Frankfort C., et al. The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheumatol 17 6 (1999) 689-697
22. Kroot E.J., de Jong B.A., van Leeuwen M.A., Swinkels H., van den Hoogen F.H., van't Hof M., et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 43 8 (2000) 1831-1835
23. Meyer O., Nicaise-Roland P., Santos M.D., Labarre C., Dougados M., Goupille P., et al. Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis Res Ther 8 2 (2006) R40
24. Nell-Duxneuner V., Machold K., Stamm T., Eberl G., Heinzl H., Hoefler E., et al. Autoantibody profiling in patients with very early rheumatoid arthritis - a follow-up study. Ann Rheum Dis (2009)
25. Syversen S.W., Gaarder P.I., Goll G.L., Odegard S., Haavardsholm E.A., Mowinckel P., et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 67 2 (2008) 212-217
26. Bukhari M., Thomson W., Naseem H., Bunn D., Silman A., Symmons D., et al. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum 56 9 (2007) 2929-2935
27. Shovman O., Gilburd B., Zandman-Goddard G., Sherer Y., Orbach H., Gerli R., et al. The diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis. Clin Dev Immunol 12 3 (2005) 197-202
28. Huizinga T.W., Amos C.I., van der Helm-van Mil A.H., Chen W., van Gaalen F.A., Jawaheer D., et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 52 11 (2005) 3433-3438
29. Kapitany A., Szabo Z., Lakos G., Aleksza M., Vegvari A., Soos L., et al. Associations between serum anti-CCP antibody, rheumatoid factor levels and HLA-DR4 expression in Hungarian patients with rheumatoid arthritis. Isr Med Assoc J 10 1 (2008) 32-36
30. Goeb V., Dieude P., Daveau R., Thomas-L'otellier M., Jouen F., Hau F., et al. Contribution of PTPN22 1858T, TNFRII 196R and HLA-shared epitope alleles with rheumatoid factor and anti-citrullinated protein antibodies to very early rheumatoid arthritis diagnosis. Rheumatology (Oxford) 47 8 (2008) 1208-1212
31. de Vries R.R., Huizinga T.W., and Toes R.E. Redefining the HLA and RA association: to be or not to be anti-CCP positive. J Autoimmun 25 (2005) 21-25 [Suppl]
32. Poor G., Nagy Z.B., Schmidt Z., Brozik M., Meretey K., and Gergely Jr. P. Genetic background of anticyclic citrullinated peptide autoantibody production in Hungarian patients with rheumatoid arthritis. Ann N Y Acad Sci 1110 (2007) 23-32
33. van der Helm-van Mil A.H., Verpoort K.N., le Cessie S., Huizinga T.W., de Vries R.R., and Toes R.E. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 56 2 (2007) 425-432
34. Ding B., Padyukov L., Lundstrom E., Seielstad M., Plenge R.M., Oksenberg J.R., et al. Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis Rheum 60 1 (2009) 30-38
35. Verpoort K.N., Cheung K., Ioan-Facsinay A., van der Helm-van Mil A.H., de Vries-Bouwstra J.K., Allaart C.F., et al. Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthritis Rheum 56 12 (2007) 3949-3952
36. Farago B., Talian G.C., Komlosi K., Nagy G., Berki T., Gyetvai A., et al. Protein tyrosine phosphatase gene C1858T allele confers risk for rheumatoid arthritis in Hungarian subjects. Rheumatol Int (2008)
37. Feitsma A.L., Toes R.E., Begovich A.B., Chokkalingam A.P., de Vries R.R., Huizinga T.W., et al. Risk of progression from undifferentiated arthritis to rheumatoid arthritis: the effect of the PTPN22 1858T-allele in anti-citrullinated peptide antibody positive patients. Rheumatology (Oxford) 46 7 (2007) 1092-1095
38. Thabet M.M., Huizinga T.W., Marques R.B., Stoeken-Rijsbergen G., Bakker A.M., Kurreeman F.A., et al. The contribution of Fc gamma receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA positive rheumatoid arthritis. Ann Rheum Dis (2008)
39. Klareskog L., Padyukov L., Lorentzen J., and Alfredsson L. Mechanisms of disease: Genetic susceptibility and environmental triggers in the development of rheumatoid arthritis. Nat Clin Pract Rheumatol 2 8 (2006) 425-433
40. Pedersen M., Jacobsen S., Garred P., Madsen H.O., Klarlund M., Svejgaard A., et al. Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum 56 5 (2007) 1446-1453